Abstract
A production of the soluble factor activity in culture fluids of murine splenic mononuclear cells (SMNC) treated with SSM, an immunopotentiator extracted from Mycobacterium tuberculosis strain Aoyama B, was investigated. The soluble factor activity was determined as a mitogenic activity released from SMNC of mice previously treated with a 500 μg/kg dose of SSM (primed SMNC). The mitogenic activity was produced when primed SMNC were challenged in vitro with SSM at a concentration of 5 μg/ml. The activity was not produced in culture fluids of primed SMNC treated with anti-Thy 1.2 or anti-Lyt 1.2 monoclonal antibody plus complement followed by a challenge with SSM. However, the production of the activity was not affected by pretreatment of primed SMNC with anti-Lyt 2.2 monoclonal antibody plus complement. Since the non-specific resistance to tumors of mice stimulated with SSM was not demonstrated in mice depleted of Thy 1+ and Lyt 1+ T-cells, and Lyt 1+ T-cells from SSM-treated mice did not show any direct cytotoxic activities against tumor cells in vitro, the soluble factor released from Lyt 1+ T-cells by SSM stimulation may play an important role in developing the non-specific resistance of mice treated with SSM.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 285-290 |
| Number of pages | 6 |
| Journal | Anticancer Research |
| Volume | 10 |
| Issue number | 2 A |
| State | Published - 1990 |
| Externally published | Yes |
Fingerprint
Keywords
- human type Tubercle bacilli
- immunomodulator
- mitogenic factor
- splenic Lyt 1 T-cells
- SSM
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Release of a mitogenic factor by splenic Lyt 1+ T-cells from mice treated with SSM, an immunomodulator extracted from human type tubercle bacilli. / Pollard, Richard B; Schmitt, D. A.; Sasaki, H.; Hayashi, Y.; Suzuki, F.
In: Anticancer Research, Vol. 10, No. 2 A, 1990, p. 285-290.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Release of a mitogenic factor by splenic Lyt 1+ T-cells from mice treated with SSM, an immunomodulator extracted from human type tubercle bacilli
AU - Pollard, Richard B
AU - Schmitt, D. A.
AU - Sasaki, H.
AU - Hayashi, Y.
AU - Suzuki, F.
PY - 1990
Y1 - 1990
N2 - A production of the soluble factor activity in culture fluids of murine splenic mononuclear cells (SMNC) treated with SSM, an immunopotentiator extracted from Mycobacterium tuberculosis strain Aoyama B, was investigated. The soluble factor activity was determined as a mitogenic activity released from SMNC of mice previously treated with a 500 μg/kg dose of SSM (primed SMNC). The mitogenic activity was produced when primed SMNC were challenged in vitro with SSM at a concentration of 5 μg/ml. The activity was not produced in culture fluids of primed SMNC treated with anti-Thy 1.2 or anti-Lyt 1.2 monoclonal antibody plus complement followed by a challenge with SSM. However, the production of the activity was not affected by pretreatment of primed SMNC with anti-Lyt 2.2 monoclonal antibody plus complement. Since the non-specific resistance to tumors of mice stimulated with SSM was not demonstrated in mice depleted of Thy 1+ and Lyt 1+ T-cells, and Lyt 1+ T-cells from SSM-treated mice did not show any direct cytotoxic activities against tumor cells in vitro, the soluble factor released from Lyt 1+ T-cells by SSM stimulation may play an important role in developing the non-specific resistance of mice treated with SSM.
AB - A production of the soluble factor activity in culture fluids of murine splenic mononuclear cells (SMNC) treated with SSM, an immunopotentiator extracted from Mycobacterium tuberculosis strain Aoyama B, was investigated. The soluble factor activity was determined as a mitogenic activity released from SMNC of mice previously treated with a 500 μg/kg dose of SSM (primed SMNC). The mitogenic activity was produced when primed SMNC were challenged in vitro with SSM at a concentration of 5 μg/ml. The activity was not produced in culture fluids of primed SMNC treated with anti-Thy 1.2 or anti-Lyt 1.2 monoclonal antibody plus complement followed by a challenge with SSM. However, the production of the activity was not affected by pretreatment of primed SMNC with anti-Lyt 2.2 monoclonal antibody plus complement. Since the non-specific resistance to tumors of mice stimulated with SSM was not demonstrated in mice depleted of Thy 1+ and Lyt 1+ T-cells, and Lyt 1+ T-cells from SSM-treated mice did not show any direct cytotoxic activities against tumor cells in vitro, the soluble factor released from Lyt 1+ T-cells by SSM stimulation may play an important role in developing the non-specific resistance of mice treated with SSM.
KW - human type Tubercle bacilli
KW - immunomodulator
KW - mitogenic factor
KW - splenic Lyt 1 T-cells
KW - SSM
UR - http://www.scopus.com/inward/record.url?scp=0025351170&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025351170&partnerID=8YFLogxK
M3 - Article
C2 - 2346302
AN - SCOPUS:0025351170
VL - 10
SP - 285
EP - 290
JO - Anticancer Research
JF - Anticancer Research
SN - 0250-7005
IS - 2 A
ER -